Candesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe

坎地沙坦西酯/瑞舒伐他汀钙/依折麦布

Report date: 2024/10/23 20:00:35
NME

Base Information

Drug NameCandesartan Cilexetil/Rosuvastatin Calcium/Ezetimibe
Drug Alias NameCandesartan/Rosuvastatin/Ezetimibe
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsHMG-CoA reductase inhibitorsNiemann-Pick C1-like protein 1 inhibitors +[4] 
TargetsAngiotensin II Receptor Type 1HMG-CoA reductaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHyperlipoproteinemia Type IIHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Candesartan CilexetilRosuvastatin CalciumEzetimibe
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHyundai Pharm. Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHyundai Pharm. Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperlipoproteinemia Type IIHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A